NasdaqCM:AKER

Stock Analysis Report

Executive Summary

Akers Biosciences, Inc., together with its subsidiaries, develops, produces, and sells rapid screening and testing products designed to deliver medical devices to healthcare providers and consumers in the United States, the People’s Republic of China, and internationally.

Risk Analysis

Earnings have declined by -14.17% per year over past 5 years

Has less than 1 year of cash runway

Does not have a meaningful market cap ($4M)

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 3 more risks


Snowflake Analysis

Adequate balance sheet and overvalued.


Similar Companies

OraSure Technologies

NasdaqGS:OSUR

Share Price & News

How has Akers Biosciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AKER's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

3.1%

AKER

2.0%

US Medical Equipment

0.8%

US Market


1 Year Return

-89.4%

AKER

29.1%

US Medical Equipment

25.1%

US Market

Return vs Industry: AKER underperformed the US Medical Equipment industry which returned 28.4% over the past year.

Return vs Market: AKER underperformed the US Market which returned 24.7% over the past year.


Shareholder returns

AKERIndustryMarket
7 Day3.1%2.0%0.8%
30 Day10.9%4.1%3.1%
90 Day-64.5%12.7%10.9%
1 Year-89.4%-89.4%30.1%29.1%27.7%25.1%
3 Year-98.5%-98.5%96.1%90.4%51.3%41.6%
5 Year-99.5%-99.5%130.3%105.7%77.2%57.6%

Price Volatility Vs. Market

How volatile is Akers Biosciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Akers Biosciences undervalued compared to its fair value and its price relative to the market?

0.51x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate AKER's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate AKER's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: AKER is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: AKER is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AKER's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AKER is good value based on its PB Ratio (0.5x) compared to the US Medical Equipment industry average (4.1x).


Next Steps

Future Growth

How is Akers Biosciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

19.6%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Akers Biosciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Akers Biosciences performed over the past 5 years?

-14.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AKER is currently unprofitable.

Growing Profit Margin: AKER is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AKER is unprofitable, and losses have increased over the past 5 years at a rate of -14.2% per year.

Accelerating Growth: Unable to compare AKER's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AKER is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (31%).


Return on Equity

High ROE: AKER has a negative Return on Equity (-177.49%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Akers Biosciences's financial position?


Financial Position Analysis

Short Term Liabilities: AKER's short term assets ($4.3M) exceed its short term liabilities ($1.4M).

Long Term Liabilities: AKER has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: AKER is debt free.

Reducing Debt: AKER had no debt 5 years ago.


Balance Sheet

Inventory Level: AKER has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if AKER's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AKER has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: AKER has less than a year of cash runway if free cash flow continues to reduce at historical rates of -17.9% each year


Next Steps

Dividend

What is Akers Biosciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate AKER's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate AKER's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AKER's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AKER's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AKER's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Akers Biosciences's salary, the management and board of directors tenure and is there insider trading?

1.3yrs

Average management tenure


CEO

Akers Biosciences has no CEO, or we have no data on them.


Management Age and Tenure

1.3yrs

Average Tenure

63yo

Average Age

Experienced Management: AKER's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Age and Tenure

0.2yrs

Average Tenure

53yo

Average Age

Experienced Board: AKER's board of directors are not considered experienced ( 0.2 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$555,55007 Jan 20
Hudson Bay Capital Management LP
EntityCompany
Shares184,578
Max PriceUS$3.10

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 44%.


Management Team

  • Howard Yeaton (64yo)

    Interim Chief Financial Officer

    • Tenure: 1.3yrs
    • Compensation: US$426.85k
  • Chris Schreiber (54yo)

    Executive Chairman of the Board

    • Tenure: 0.2yrs
    • Compensation: US$100.00k
  • Gary Rauch (63yo)

    VP of Finance & Treasurer

    • Tenure: 6.4yrs
    • Compensation: US$161.86k

Board Members

  • Rob Schroeder (52yo)

    Independent Director

    • Tenure: 0.2yrs
  • Josh Silverman (49yo)

    Independent Lead Director

    • Chris Schreiber (54yo)

      Executive Chairman of the Board

      • Tenure: 0.2yrs
      • Compensation: US$100.00k
    • Bill White (58yo)

      Independent Director

      • Tenure: 2.4yrs
      • Compensation: US$100.00k
    • Bob Hoban

      Member of Advisory Board

      • Tenure: 0.08yrs
    • Michael Patterson

      Member of Advisory Board

      • Tenure: 0.08yrs

    Company Information

    Akers Biosciences, Inc.'s company bio, employee growth, exchange listings and data sources


    Key Information

    • Name: Akers Biosciences, Inc.
    • Ticker: AKER
    • Exchange: NasdaqCM
    • Founded: 1989
    • Industry: Health Care Equipment
    • Sector: Healthcare
    • Market Cap: US$3.973m
    • Shares outstanding: 1.14m
    • Website: https://www.akersbio.com

    Number of Employees


    Location

    • Akers Biosciences, Inc.
    • 201 Grove Road
    • Thorofare
    • New Jersey
    • 8086
    • United States

    Listings

    TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
    AKERNasdaqCM (Nasdaq Capital Market)YesCommon SharesUSUSDMay 2002
    DQS3DB (Deutsche Boerse AG)YesCommon SharesDEEURMay 2002
    AKRAIM (London Stock Exchange AIM Market)COM SHS NPV (REG S)GBGBPNov 2013

    Biography

    Akers Biosciences, Inc., together with its subsidiaries, develops, produces, and sells rapid screening and testing products designed to deliver medical devices to healthcare providers and consumers in the United States, the People’s Republic of China, and internationally. Its products include BreathScan, a disposable breath alcohol detector; PIFA Heparin/PF4 and PIFA PLUSS PF4 rapid tests for Heparin/PF4 antibodies to detect an allergy to the used blood thinner, Heparin; seraSTAT, a rapid blood cell separator; Tri-Cholesterol ‘Check’, a rapid test for total and high density lipoprotein cholesterol and estimates low density lipo protein; and BreathScan OxiCHek that detects aldehydes or oxidative stress in exhaled human breath. The company was founded in 1989 and is headquartered in Thorofare, New Jersey. 


    Company Analysis and Financial Data Status

    All financial data provided by Standard & Poor's Capital IQ.
    DataLast Updated (UTC time)
    Company Analysis2020/01/22 00:26
    End of Day Share Price2020/01/21 00:00
    Earnings2019/09/30
    Annual Earnings2018/12/31


    Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.